Robert J. Glynn

Comparative safety of gout treatment strategies on cardiovascular outcomes using observational data: Clone-censor-weight target trial emulation approach.

Yoshida K, Liu J, Desai RJ, Glynn RJ, Solomon DH, Kim SC.

Epidemiology. 2023 Mar 16. PMID: 36943798

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.

Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE.

Lancet. 2023 Mar 03. PMID: 36893777

Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion.

Schneeweiss MC, Savage TJ, Wyss R, Jin Y, Schoder K, Merola JF, Sidbury R, Oduol T, Schneeweiss S, Glynn RJ.

JAMA Dermatol. 2023 Mar 01. 159(3):289-298. PMID: 36753234

Relationship between Claims-Based Frailty Index and Eye Care Utilization among Medicare Beneficiaries with Glaucoma.

Halawa OA, Kang J, Parikh AA, Oh G, Glynn RJ, Friedman DS, Kim DH, Zebardast N.

Ophthalmology. 2023 Jan 31. PMID: 36731798

Estimation and testing for clustered interval-censored bivariate survival data with application using the semi-parametric version of the Clayton-Oakes model.

Rosner B, Bay C, Glynn RJ, Ying GS, Maguire MG, Lee MT.

Lifetime Data Anal. 2023 Jan 20. PMID: 36670299

Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial.

Taqueti VR, Shah AM, Everett BM, Pradhan AD, Piazza G, Bibbo C, Hainer J, Morgan V, Carolina do A H de Souza A, Skali H, Blankstein R, Dorbala S, Goldhaber SZ, Le May MR, Chow BJW, deKemp RA, Hage FG, Beanlands RS, Libby P, Glynn RJ, Solomon SD, Ridker PM, Di Carli MF.

JACC Basic Transl Sci. 2023 Feb. 8(2):141-151. PMID: 36908662

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.

Shin H, Schneeweiss S, Glynn RJ, Patorno E.

Ann Intern Med. 2022 12. 175(12):W155. PMID: 36534995

Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.

Solomon DH, Giles JT, Liao KP, Ridker PM, Rist PM, Glynn RJ, Broderick R, Lu F, Murray MT, Vanni K, Santacroce LM, Abohashem S, Robson PM, Fayad Z, Mani V, Tawakol A, Bathon J.

Ann Rheum Dis. 2023 03. 82(3):324-330. PMID: 36450449

Canakinumab's Effect Against Subsequent Gout Flares and High-Sensitivity C-Reactive Protein Levels: A Causal Mediation Analysis.

Yoshida K, Glynn RJ, Choi HK, Everett BM, Li Y, MacFadyen JG, Ridker PM, Solomon DH.

Arthritis Care Res (Hoboken). 2023 Apr. 75(4):817-824. PMID: 34874116

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM.

N Engl J Med. 2022 Nov 24. 387(21):1923-1934. PMID: 36342113